Companies will exploit Anagnostics’ hybcell platform for diagnostics and drug development.

Austrian firms Vela Laboratories and Anagnostics Bioanalysis are teaming up to offer Anagnostics’ hybcell DNA and protein microarray technology to the pharma and biotech industries for applications in clinical diagnostics and drug development.

Anagnostics claims the hybcell platform is the world’s first microarray technology based on the use of cylinders rather than slides. The platform combines DNA- or protein-based hybcell tests for drug development and clinical diagnostic applications with the fully automated, hyborg instrument that carries out all hybcell test processing, from hybridization to liquid exchange, cycling, and scanning.

The partnership between Vela and Anagnostics will initially offer the hybcell technology for use in companion diagnostics in clinical studies, and also position the technology as an alternative to surface plasmon resonance methods used in affinity and immunogenicity drug testing applications.

The firms’ deal follows on from yesterday’s announcement by Anagnostics that it had signed up Danish firm Ramcon as distributor for its hybcell tests in the Nordic countries. Ramcon will market and distribute Anagnostics’ existing hybcell DoA urine and hybcell DoA saliva drug screening tests, and its hybcell Oncogenesis Tissues pharmacogenomic tests.

Vela is GMP-certified contract laboratory specialized in offering analytical protein characterization services for protein-based biopharmaceuticals and biosimilars. The firm’s expertise spans a full range of bioanalytics services for drug development and preclinical/clinical trials. 

Previous articleU.S. Patent Law Retains Key Differences with Europe and Canada
Next articleEndece, MRF to Progress Myelin Regeneration Candidates into Clinic